CRVO Valuation

CervoMed Inc

Add to Watchlist

Advanced Chart

10.690

+0.595(5.894%)1D

Overview
Forecast
Valuation
Earnings

CRVO Relative Valuation

CRVO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRVO is overvalued; if below, it's undervalued.

Historical Valuation

CervoMed Inc (CRVO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29.94 is considered Overvalued compared with the five-year average of -6.07. The fair price of CervoMed Inc (CRVO) is between 2.30 to 6.77 according to relative valuation methord. Compared to the current price of 10.69 USD , CervoMed Inc is Overvalued By 57.93%.

Relative Value

Fair Zone

2.30-6.77

Current Price：10.69

57.93%

Overvalued

-4.28

Trailing

Forward

-1.19

EV/EBITDA

CervoMed Inc. (CRVO) has a current EV/EBITDA of -1.19. The 5-year average EV/EBITDA is -3.48. The thresholds are as follows: Strongly Undervalued below -9.76, Undervalued between -9.76 and -6.62, Fairly Valued between -0.34 and -6.62, Overvalued between -0.34 and 2.79, and Strongly Overvalued above 2.79. The current Forward EV/EBITDA of -1.19 falls within the Historic Trend Line -Fairly Valued range.

-1.67

EV/EBIT

CervoMed Inc. (CRVO) has a current EV/EBIT of -1.67. The 5-year average EV/EBIT is -3.60. The thresholds are as follows: Strongly Undervalued below -9.98, Undervalued between -9.98 and -6.79, Fairly Valued between -0.42 and -6.79, Overvalued between -0.42 and 2.77, and Strongly Overvalued above 2.77. The current Forward EV/EBIT of -1.67 falls within the Historic Trend Line -Fairly Valued range.

28.53

CervoMed Inc. (CRVO) has a current PS of 28.53. The 5-year average PS is 14.30. The thresholds are as follows: Strongly Undervalued below -1.30, Undervalued between -1.30 and 6.50, Fairly Valued between 22.10 and 6.50, Overvalued between 22.10 and 29.90, and Strongly Overvalued above 29.90. The current Forward PS of 28.53 falls within the Overvalued range.

-2.00

P/OCF

CervoMed Inc. (CRVO) has a current P/OCF of -2.00. The 5-year average P/OCF is -7.31. The thresholds are as follows: Strongly Undervalued below -35.19, Undervalued between -35.19 and -21.25, Fairly Valued between 6.63 and -21.25, Overvalued between 6.63 and 20.57, and Strongly Overvalued above 20.57. The current Forward P/OCF of -2.00 falls within the Historic Trend Line -Fairly Valued range.

-2.00

P/FCF

CervoMed Inc. (CRVO) has a current P/FCF of -2.00. The 5-year average P/FCF is -4.93. The thresholds are as follows: Strongly Undervalued below -14.64, Undervalued between -14.64 and -9.78, Fairly Valued between -0.07 and -9.78, Overvalued between -0.07 and 4.79, and Strongly Overvalued above 4.79. The current Forward P/FCF of -2.00 falls within the Historic Trend Line -Fairly Valued range.

CervoMed Inc (CRVO) has a current Price-to-Book (P/B) ratio of 2.96. Compared to its 3-year average P/B ratio of 6.06 , the current P/B ratio is approximately -51.17% higher. Relative to its 5-year average P/B ratio of 6.06, the current P/B ratio is about -51.17% higher. CervoMed Inc (CRVO) has a Forward Free Cash Flow (FCF) yield of approximately -24.96%. Compared to its 3-year average FCF yield of -19.20%, the current FCF yield is approximately 29.97% lower. Relative to its 5-year average FCF yield of -19.20% , the current FCF yield is about 29.97% lower.

2.79

P/B

Median3y

6.06

Median5y

6.06

-26.19

FCF Yield

Median3y

-19.20

Median5y

-19.20

Competitors Valuation Multiple

The average P/S ratio for CRVO's competitors is 5.34, providing a benchmark for relative valuation. CervoMed Inc Corp (CRVO) exhibits a P/S ratio of 28.53, which is 434.06% above the industry average. Given its robust revenue growth of -46.56%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Research Solutions Inc

1.92

4.50%

103.22M

Performance Decomposition

Market capitalization of CRVO decreased by 29.65% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -70.44 to -356.05.

The secondary factor is the Revenue Growth, contributed -46.56%to the performance.

Overall, the performance of CRVO in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-46.56%

3.29M → 1.76M

Revenue Growth

405.47%

-70.44 → -356.05

Margin Expansion

-388.56%

1.44 → -4.15

P/E Change

-29.65%